Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir

Review

(1789) Views  (534) Full article downloads

Authors: Michael Neely, Andrea Kovacs

Published Date July 2009 Volume 2009:5 Pages 595 - 615

DOI: http://dx.doi.org/10.2147/TCRM.S4595

Michael Neely, Andrea Kovacs

University of Southern California Keck School of Medicine, Department of Pediatrics, Division of infectious Diseases, Los Angeles, CA, USA

Abstract: Darunavir is currently the most recently approved HIV-1 protease inhibitor. It is approved for twice-daily dosing with ritonavir in treatment-experienced patients as young as 6 years of age and is available in numerous pill strengths. Emergence of darunavir-specific mutations is generally slow; therefore it can retain activity against viral strains that are resistant to other protease inhibitors, including tipranavir. Darunavir pharmacokinetics, clinical efficacy, resistance mutations and pharmacodynamics, and adverse effects are reviewed here. Substantial data support its use as a potent, well-tolerated option for salvage therapy in highly treatment experienced children and adolescents.

Keywords: darunavir, protease inhibitors, treatment, child, adolescent